ELVN · Enliven Therapeutics

The thesis

Enliven Therapeutics is modestly more likely than not to beat the S&P 500 over the next three months. The company has the cash and the Food and Drug Administration (FDA) agreement it needs to start ENABLE-2, its pivotal trial of relcobatinib in chronic myeloid leukemia (CML), and it guides the start for before year-end 2026. A disclosed first patient or site activation settles whether that timetable holds.

The shares closed at $48.31 on 12 November 2026, down from $51.19 on 11 November 2026 and 22.5% below the 52-week intraday high of $62.32 set on 5 August 2026. The 3-month change is −17.9%. The close is above the 50-day average of $46.65 and the 200-day average of $43.72, both as of 12 November 2026.

The third-quarter report on 5 November 2026 reaffirmed the timetable and added no new clinical results. The trial design question closed with the October 2026 FDA alignment announcement. What remains is execution: the first patient dosed.

Bullish and bearish views on Enliven Therapeutics, Inc.

The bull case on Enliven Therapeutics, Inc. (ELVN), in brief: the timetable held at the latest report. The bear case: the shares gave back part of the gain.

Bull case

• The timetable held at the latest report. On 5 November 2026 Enliven said it is on track to initiate ENABLE-2 before year-end 2026. About 450 previously treated CML patients will be randomized 1:1 to relcobatinib 80 mg daily or an investigator-chosen second-generation tyrosine kinase inhibitor (TKI).
• One trial could support two approvals. Per the 5 November 2026 release, major molecular response at week 24 is the primary endpoint and could support accelerated approval. Response at week 96 is the key secondary endpoint and could support full approval.
• Cash covers the guided plan. Cash, cash equivalents and marketable securities were $884.4 million at 30 September 2026, per the third-quarter release and 10-Q. Enliven guides runway into 2030.
• Analyst targets sit well above the shares. Guggenheim reiterated its Buy rating and $78 target on 6 November 2026, per Benzinga. MarketBeat counted 10 Buy and 2 Sell ratings with an average target of $75.44 on 5 November 2026.
• Early activity supports a controlled test. In the 80 mg Phase 1b cohort, reported 11 June 2026, major molecular response was 61% among 28 evaluable patients. Among 21 evaluable patients, 48% reached it by 24 weeks. Both groups are small and had no control arm.
• Shares recovered from the October low. The close was $44.79 on 5 November 2026 and $51.55 on 9 November 2026, per adjusted daily closes, after the report confirmed the start timing.

Bear case

• The shares gave back part of the gain. They closed at $51.19 on 11 November 2026 and $48.31 on 12 November 2026, after three sessions between $51.19 and $51.55. A year-end start with no new data leaves few company-specific events before the first patient.
• Spending rises before the big trial starts. Research and development expense was $28.0 million in the third quarter against $18.2 million a year earlier. Net loss was $27.7 million against $20.1 million, per the 5 November 2026 release.
• The comparator is an approved drug class. ENABLE-2 tests relcobatinib against established second-generation TKIs. A miss on week-24 major molecular response would break the clinical case.
• Insiders keep selling. SEC Form 4 filings show the chief financial officer sold 6,018 shares at $38.48 and the chief medical officer sold 5,000 shares at $38.47, both on 19 October 2026 under Rule 10b5-1 plans. Director J. Scott Garland sold 13,000 shares at $46.67 on 1 October 2026.
• The share count grew in June. The 10-Q records 10,533,334 common shares issued in the June 2026 public offering. Common shares outstanding were 73,595,132 on 28 October 2026.

Price setup

Adjusted daily closes show $44.79 on 5 November 2026, $49.43 on 6 November 2026, $51.55 on 9 November 2026, $51.20 on 10 November 2026, $51.19 on 11 November 2026 and $48.31 on 12 November 2026. The 3-month reference close was $58.82 on 14 August 2026.

The 52-week intraday high is $62.32 on 5 August 2026. The 52-week closing low is $15.14 on 6 January 2026, after the January data release that lifted the shares.

The 50-day average of $46.65 sits 3.5% below the last close. The 200-day average of $43.72 is lower still. A close under the 50-day average would put the shares back in the $44 to $47 range where they traded from late September to 5 November 2026. The June 2026 offering price is the main reference far below the market.

Catalysts ahead

• 16 November 2026: Jefferies Global Healthcare Conference, London, 16 November to 19 November 2026, with a webcast fireside chat. A public management appearance before the guided trial start, and a chance to update ENABLE-2 timing.
• ~31 December 2026 (est.): End of the guided window for the ENABLE-2 start. A disclosed first patient or site activation confirms the timetable; a move into 2027 would break the near-term case.
• ~30 June 2027 (est.): Phase 1/2 relcobatinib data update, guided for mid-2027. The next clinical readout after the trial start; it tests whether response rates hold in more patients and longer follow-up.

What would change the view

A weekly close below $37.50, the price of Enliven's June 2026 public offering, which would put the shares under the price new investors paid the company. A company disclosure moving the ENABLE-2 start into 2027 would also break the case.

The risks this note tracks, each with what would confirm it:

• ENABLE-2 enrollment slips past the guided end of 2026. Confirmed by: a company disclosure moving the start into 2027, or no documented enrollment start by 31 December 2026.
• Early single-arm response rates fail to translate into a win against second-generation TKIs. Confirmed by: ENABLE-2 missing its week-24 major molecular response endpoint when it reads out.
• Insider sales and the enlarged share count weigh on the shares. Confirmed by: further SEC Form 4 sales by officers and directors after the 19 October 2026 filings.
• Phase 3 costs erode the guided cash runway faster than planned. Confirmed by: a company report shortening runway guidance from into 2030 to an earlier period.

What it trades with

Enliven is a single-asset clinical-stage company with no product revenue, so events in the relcobatinib program drive most of its moves. Between those events the shares tend to trade with small- and mid-cap biotech sentiment and with appetite for equity financings. The 10.4% gain on 6 November 2026 came without company news, which shows how much day-to-day movement is independent of the business. CML is served by approved TKIs, so competitor trial results and label changes can move the shares without Enliven news.